Anthem Biosciences Ltd

During the earnings conference call held on July 22, 2026, management reported consolidated revenues of Rs. 418 crores for Q1 FY27, with the CRDMO business contributing 81.5% of this total. The EBITDA was Rs. 176 crores, reflecting an EBITDA margin of 39.6%. Management noted a strong underlying demand despite timing shifts in deliveries, with a net cash position of Rs. 1,720 crores as of June 30, 2026. They highlighted a disciplined focus on cost efficiencies and yield optimization, which contributed to year-over-year improvements in both EBITDA and PAT margins. Management also discussed capacity utilization across various units, indicating a ramp-up in Unit 3 and plans for Unit 4's commissioning by the end of FY28. They expressed confidence in sustaining revenue growth aligned with historical performance, despite a softer quarter. The call concluded with management emphasizing their commitment to transparency and long-term growth.

Management provided a balanced overview of performance and future plans without overly optimistic or pessimistic language.